期刊文献+

超常规量阿托伐他汀对急性心肌梗死患者早期血管内皮功能的影响 被引量:10

Influence of over regular atrovastatin on early stage of vascular endothelial function in patients with acute myocardial infarction
下载PDF
导出
摘要 目的 :探讨短期大剂量阿托伐他汀对急性心肌梗死 (AMI)患者血管内皮功能改善的早期疗效。方法 :将68例AMI患者分为大剂量组和常规量组 ,于AMI后24h内给予口服不同剂量的阿托伐他汀2周 ,分别测定治疗前后的血脂 (TC、TG、LDL -C、HDL -C)、反应性充血引起的肱动脉内径舒张率 (ΔD % )、血浆内皮素1(ET -1)、血浆组织型纤溶酶原激活物 (t-PA)以及血浆纤溶酶原激活物抑制物1(PAI -1)。结果 :大剂量组服药2周后血脂TC、TG、LDL -C下降 (P<0.05) ,(D %、t -PA明显增高 (P<0.01) ,ET -1、PAI -1明显减低 (P<0.01) ;常规量组上述指标均无变化。结论 :对AMI患者给予短期大剂量阿托伐他汀治疗在早期提高血管内皮功能方面明显优于常规剂量。 Objective: To investigate the previous effects of large dose atrovastatin in short time on vascular endothelial function in patients with acute myocardial infarction (AMI). Methods:68 patients with AMI were randomly divided into large dose group and regular dose group and took different dose atrovastatin for 2 weeks in 24 hour of AMI. Lipid(TC,TG,LDL-C,HDL-C),brachial artery relaxant rate of reaction to congestion((D%),plasma endothelin-1(ET-1),tissue type plasmiogen activator(t-PA) and plasmiogen activator inhibitor-1(PAI-1) were measured before and after treatment of atrovastatin.Results: After 2 weeks of taking atrovastatin in large dose group, lipid(TC,TG,LDL-C) level was decreased(P<0.05). (D%, t-PA were markedly increased(P<0.01). ET-1, PAI-1 were markedly decreased(P<0.01).But there were not changed of above parameters in regular dose group . Conclusion: Effects of large dose atrovastatin treatment on AMI patients in short time for increasing previous vascular endothelial function is better than that of regular dose.
作者 袁晓华 张蕴
出处 《天津医科大学学报》 2004年第2期170-172,共3页 Journal of Tianjin Medical University
基金 天津市自然科学基金课题 (项目编号 :963609711)
关键词 阿托伐他汀 血管内皮功能 急性心肌梗死 Atrovastatin Vascular endothelial function Acute myocardial infarction
  • 相关文献

二级参考文献10

  • 1Takai Y,Sasaki T,Tanaka K, et al.Rho as a regulator of the cytoskeleton[].Trends in Biochemical Sciences.1995
  • 2Corsini A,Pazzucconi F,Pfister P, et al.Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin[].The Lancet.1996
  • 3Akira S,Taga T,Kishimoto T.Interleukin-6 in biology and medicine[].Avd Immunol.1993
  • 4Ballantyne CM,Herd FA,Ferlic LL,et al.Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy[].Circulation.1999
  • 5Scandinavian Simvastatin Survival Study Group.Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian simvastatin survival study(4S)[].The Lancet.1994
  • 6Hughes AD.The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering[].Journal of Human Hypertension.1996
  • 7Vrtovsnik F,Couette S,Prie D,et al.Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway[].Kidney International.1997
  • 8Larner J,Jane J,Laws E,et al.A phase Ⅰ-Ⅱ trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme[].American Journal of Clinical Oncology.1998
  • 9Maggard MA,Ke B,Wang T,et al.Effects of pravastatin on chronic rejection of rat cardiac allografts[].Transplantation.1998
  • 10Raiteri M,Arnaboldi L,McGeady P,et al.Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation[].Journal of Pharmacology and Experimental Therapeutics.1997

共引文献6

同被引文献132

引证文献10

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部